BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA

Reuters

Jan 12

Jan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:

PIERRE FABRE PHARMACEUTICALS: ON JAN 9, GOT COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BLA FROM U.S. FDA
PIERRE FABRE: IN NEW CRL, FDA SAID IT NO LONGER CONSIDERS PREVIOUSLY ACCEPTED SINGLE-ARM ALLELE STUDY TO BE ENOUGH TO SUPPORT ACCELERATED APPROVAL

Source text: ID:nPn86TQCza

Further company coverage: ATRA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602510421"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602510421\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602510421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602510421","market":"fut","top_or_hot":-1,"title":"BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Inc <span>ATRA.O</span>:</p><ul><li><p>PIERRE FABRE PHARMACEUTICALS: ON JAN 9, GOT COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BLA FROM U.S. FDA</p></li><li><p>PIERRE FABRE: IN NEW CRL, FDA SAID IT NO LONGER CONSIDERS PREVIOUSLY ACCEPTED SINGLE-ARM ALLELE STUDY TO BE ENOUGH TO SUPPORT ACCELERATED APPROVAL</p></li></ul><p>Source text: <span>ID:nPn86TQCza</span></p><p>Further company coverage: <span>ATRA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Inc <span>ATRA.O</span>:</p><ul><li><p>PIERRE FABRE PHARMACEUTICALS: ON JAN 9, GOT COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BLA FROM U.S. FDA</p></li><li><p>PIERRE FABRE: IN NEW CRL, FDA SAID IT NO LONGER CONSIDERS PREVIOUSLY ACCEPTED SINGLE-ARM ALLELE STUDY TO BE ENOUGH TO SUPPORT ACCELERATED APPROVAL</p></li></ul><p>Source text: <span>ID:nPn86TQCza</span></p><p>Further company coverage: <span>ATRA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATRA","symbol_name":"Atara Biotherapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD167:1","article_id":"2602510421","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602510421","pubTimestamp":1768223596,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDAJan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:PIERRE FABRE PHARMACEUTICALS: ON JAN 9,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATRA":"Atara Biotherapeutics","BK4139":"生物科技"},"translate_title":"简介-Pierre Fabre Pharmaceuticals于1月9日收到美国FDA对Tabelecleucel BLA的完整回复信","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRA":0.9},"content_text":"BRIEF-Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDAJan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:PIERRE FABRE PHARMACEUTICALS: ON JAN 9, GOT COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BLA FROM U.S. FDAPIERRE FABRE: IN NEW CRL, FDA SAID IT NO LONGER CONSIDERS PREVIOUSLY ACCEPTED SINGLE-ARM ALLELE STUDY TO BE ENOUGH TO SUPPORT ACCELERATED APPROVALSource text: ID:nPn86TQCzaFurther company coverage: ATRA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}